Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK576405/.
Yang Z, Yu M, Mei M, Chen C, Lv Y, Xiang L, et al. The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system. Nutr Metab Cardiovasc Dis. 2022;32:504–10. https://doi.org/10.1016/j.numecd.2021.10.003.
Google Scholar
Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab. 2021;23:5–29.
Google Scholar
Cabou C, Burcelin R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud. 2011;8:418–31.
Google Scholar
Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. https://doi.org/10.1016/j.molmet.2019.09.010.
Google Scholar
Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19:336–47.
Google Scholar
Nauck MA. D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21:169.
Google Scholar
Iqbal PMR, Maadarani OS, Bitar ZI. Tirzepatide-Induced Ketoacidosis in Non-Diabetic Patients. Eur J Case Rep. Intern Med. 2024;11:004357. https://doi.org/10.12890/2024_004357.
Google Scholar
Sood N, Bansal O, Garg R, Hoskote A. Euglycemic Ketoacidosis From Semaglutide in a Patient Without Diabetes. JCEM Case Rep. 2024;2:luae156. https://doi.org/10.1210/jcemcr/luae156.
Google Scholar
Palmer BF, Clegg DJ. Starvation Ketosis and the Kidney. Am J Nephrol. 2021;52:467–78. https://doi.org/10.1159/000517305.
Google Scholar
Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD. SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. J Lipid Atheroscler. 2022;11:1–19. https://doi.org/10.12997/jla.2022.11.1.1.
Google Scholar
Alghamdi M, Almulhim M, Alkhadra F, Alahmadi S, Alzahid A, Al-Mulhim A. A Liraglutide Injection Superimposing a Starvation Acidosis: a Case Report. Med Arch. 2022;76:221–3.
Google Scholar
